Prostaglandin E2

Generic Name
Prostaglandin E2
Brand Names
Cervidil, Prepidil, Prostin E2
Drug Type
Small Molecule
Chemical Formula
C20H32O5
CAS Number
363-24-6
Unique Ingredient Identifier
K7Q1JQR04M
Background

Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.

Indication

For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first d...

Associated Conditions
Gestational Trophoblastic Neoplasia
Associated Therapies
Induction of cervix ripening therapy, Medically induced abortion, Uterus evacuation
Clinical Trials
Related News

Preoperative Vaginal Dinoprostone Versus Misoprostone in Abdominal Myomectomy

Phase 3
Completed
Conditions
Myoma;Uterus
Interventions
Drug: Misoprostol
Drug: Dinoprostone
First Posted Date
2023-03-09
Last Posted Date
2023-03-09
Lead Sponsor
Beni-Suef University
Target Recruit Count
90
Registration Number
NCT05761418
Locations
šŸ‡ŖšŸ‡¬

Beni-suef university, Banī Suwayf, Egypt

Dinoprostone Induction vs. Expectant Management After PROM at Term

First Posted Date
2022-06-24
Last Posted Date
2022-06-24
Lead Sponsor
University Medical Centre Ljubljana
Target Recruit Count
70
Registration Number
NCT05430711

Labor Induction After Failed Induction With Dinoprostone.

First Posted Date
2020-10-22
Last Posted Date
2022-04-20
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
144
Registration Number
NCT04597333
Locations
šŸ‡®šŸ‡±

Rambam health care campus, Haifa, Israel

Vaginal Dinoprostone Versus Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy

Not Applicable
Conditions
Postmenopausal Bleeding
Interventions
Drug: INH
Drug: dinoprostone
First Posted Date
2020-08-05
Last Posted Date
2021-09-29
Lead Sponsor
Aswan University Hospital
Target Recruit Count
200
Registration Number
NCT04500496
Locations
šŸ‡ŖšŸ‡¬

Aswan University Hospital, Aswan, Egypt

Vaginal Dinoprostone Administration Prior to Intrauterine Device Insertion

Phase 4
Completed
Conditions
IUD Insertion Pain
Interventions
Drug: placebo
Drug: Dinoprostone
First Posted Date
2019-09-06
Last Posted Date
2020-07-31
Lead Sponsor
Cairo University
Target Recruit Count
130
Registration Number
NCT04079140
Locations
šŸ‡ŖšŸ‡¬

faculty of medicine Cairo university, Giza, Egypt

Comparison of Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Nulliparous Women

First Posted Date
2019-09-06
Last Posted Date
2020-06-30
Lead Sponsor
Cairo University
Target Recruit Count
129
Registration Number
NCT04080336
Locations
šŸ‡ŖšŸ‡¬

Ahmed Samy, Giza, Egypt

Vaginal Dinoprostone Administration Prior to an Intrauterine Device Insertion in Multiparous Women.

Phase 4
Completed
Conditions
IUD Insertion
Interventions
Drug: placebo
Drug: Dinoprostone
First Posted Date
2019-08-06
Last Posted Date
2020-03-10
Lead Sponsor
Cairo University
Target Recruit Count
160
Registration Number
NCT04046302
Locations
šŸ‡ŖšŸ‡¬

faculty of medicine Cairo university, Giza, Egypt

Vaginal Dinoprostone Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System in Women With no Previous Vaginal Delivery

Phase 4
Completed
Conditions
Intrauterine Device
Interventions
Drug: Placebo
Drug: Dinoprostone
First Posted Date
2019-08-05
Last Posted Date
2020-01-13
Lead Sponsor
Cairo University
Target Recruit Count
200
Registration Number
NCT04045548
Locations
šŸ‡ŖšŸ‡¬

faculty of medicine Cairo university, Cairo, Egypt

Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients

First Posted Date
2019-08-02
Last Posted Date
2020-09-01
Lead Sponsor
Cairo University
Target Recruit Count
150
Registration Number
NCT04044079
Locations
šŸ‡ŖšŸ‡¬

Ahmed Samy, Giza, Egypt

Cervical Preparation in Hysteroscopy

Not Applicable
Conditions
GYN Disorders
Interventions
Drug: misoprostol
Drug: dinoprostone
First Posted Date
2018-09-18
Last Posted Date
2019-01-09
Lead Sponsor
Aljazeera Hospital
Target Recruit Count
100
Registration Number
NCT03675802
Locations
šŸ‡ŖšŸ‡¬

Algazeerah, Giza, Egypt

Ā© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy